Deleobuvir
Deleobuvir
Deleobuvir (pronounced: del-e-o-bu-vir) is an experimental drug that was under development for the treatment of hepatitis C. It is a non-nucleoside inhibitor of the hepatitis C virus (HCV) polymerase, an enzyme necessary for viral replication.
Etymology
The name "Deleobuvir" is derived from the Latin roots "deleo" meaning to destroy, and "buvir" which is a common suffix for antiviral medications.
Mechanism of Action
Deleobuvir inhibits the RNA-dependent RNA polymerase of the hepatitis C virus, thereby preventing the virus from replicating its RNA and reproducing.
Clinical Trials
Deleobuvir was studied in clinical trials in combination with other antiviral drugs. However, development was discontinued in 2014 due to concerns about side effects and the availability of more effective treatments.
Related Terms
See Also
External links
- Medical encyclopedia article on Deleobuvir
- Wikipedia's article - Deleobuvir
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski